MarketInOut Stock Screener Log In | Sign Up
 

Mirum Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 07/27/2026 13:11
Mirum Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,892.71 mln
Float52.46 mln
Earnings Date07/30/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-1.64
Likely manipulated

1-Year Forecast

146
Strong upside

Relative Strength

29 / 100
Underperforming

Debt / Equity

1.34
Elevated leverage

ROE

-299
Deeply negative

Business Description

Mirum Pharmaceuticals is a Foster City, California-based company founded in 2018 that develops and sells treatments for rare liver and metabolic diseases. Its approved products include LIVMARLI, a drug for severe itching caused by Alagille syndrome, along with Cholbam and Chenodal, which address bile acid disorders and gallstones respectively. The company also has several treatments in clinical trials targeting liver disease, chronic HDV infection, and fragile X syndrome. Mirum works with a number of partners, including Pfizer, Novartis, and Sanofi, to support its research and commercial operations.

Key Fundamentals

EPS-13.46
ROE-299
RPS10.51
ROIC-21.51
ROA-102
EBITDA, mln-758
EV / EBITDA-9.88
EV / EBIT-9.56
Revenue, mln570
EV / Revenue13.14

Financial Strength

Altman Z-Score2.46
Piotroski F-Score 4 / 9
Beneish M-Score-1.64
1-Year Target Price146
Short Ratio6.69
Short % of Float15.64

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.43% 28 / 100   
1 Month -2.98% 33 / 100   
2 Months 16.17% 87 / 100   
6 Months 20.68% 86 / 100   
1 Year 118% 95 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us